Programmable nuclease technologies, especially CRISPR/Cas9 have revolutionized the field of gene editing, and have been credited with the potential to cure genetic defects. ATGC was awarded this grant to formulate and test new hyperbranched polymers for the effective packaging and delivery of Cas9 plasmid DNA, to enable its therapeutic application in vitro and in vivo. For details of the technology please search Project Number 1R42TR001711 in NIH RePORTER.
No comment